astemizole has been researched along with Benign Neoplasms in 6 studies
Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.
astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Major MDR targets in both bacterial and cancer cells are multidrug efflux systems." | 2.82 | Inhibition of the drug efflux activity of Ptch1 as a promising strategy to overcome chemotherapy resistance in cancer cells. ( Azoulay, S; Kovachka, S; Malloci, G; Mus-Veteau, I; Ruggerone, P; Simsir, M, 2022) |
| "Astemizole has gained enormous interest since it also targets important proteins involved in cancer progression, namely, ether à-go-go 1 (Eag1) and Eag-related gene (Erg) potassium channels." | 2.47 | Astemizole: an old anti-histamine as a new promising anti-cancer drug. ( Camacho, J; García-Quiroz, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kong, X | 1 |
| Chen, L | 1 |
| Jiao, L | 1 |
| Jiang, X | 1 |
| Lian, F | 1 |
| Lu, J | 1 |
| Zhu, K | 1 |
| Du, D | 1 |
| Liu, J | 1 |
| Ding, H | 1 |
| Zhang, N | 1 |
| Shen, J | 1 |
| Zheng, M | 1 |
| Chen, K | 1 |
| Liu, X | 1 |
| Jiang, H | 1 |
| Luo, C | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Zhao, Y | 1 |
| Guan, YY | 1 |
| Zhao, F | 1 |
| Yu, T | 1 |
| Zhang, SJ | 1 |
| Zhang, YZ | 1 |
| Duan, YC | 1 |
| Zhou, XL | 1 |
| Kovachka, S | 1 |
| Malloci, G | 1 |
| Simsir, M | 1 |
| Ruggerone, P | 1 |
| Azoulay, S | 1 |
| Mus-Veteau, I | 1 |
| Shah, RR | 1 |
| Stonier, PD | 1 |
| García-Quiroz, J | 1 |
| Camacho, J | 1 |
5 reviews available for astemizole and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Topics: Ectoderm; Enhancer of Zeste Homolog 2 Protein; Humans; Intercellular Signaling Peptides and Proteins | 2022 |
Inhibition of the drug efflux activity of Ptch1 as a promising strategy to overcome chemotherapy resistance in cancer cells.
Topics: Drug Design; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Hedgehog Proteins; Humans; Neopla | 2022 |
Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead.
Topics: Antineoplastic Agents; Astemizole; Cost-Benefit Analysis; Drug Repositioning; Genomics; Humans; Metf | 2019 |
Astemizole: an old anti-histamine as a new promising anti-cancer drug.
Topics: Antineoplastic Agents; Astemizole; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Ether-A- | 2011 |
1 other study available for astemizole and Benign Neoplasms
| Article | Year |
|---|---|
Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Topics: Astemizole; Binding, Competitive; Catalysis; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; | 2014 |